Golden Meditech Holdings Limited provided earnings guidance for the year ended 31 March 2018. The Group expects to record a net profit of approximately HKD 3,363 million for the year ended 31 March 2018 as compared to a net loss of approximately HKD 171 million recorded by the Group for the year ended 31 March 2017. The Net Profit is mainly attributable to recognition of a one off net gain on disposal of 65.4% of the enlarged issued share capital of Global Cord Blood Corporation (formerly known as China Cord Blood Corporation) of approximately HKD 3,790 million, details of which are disclosed in the Company's circular dated 6 March 2017. Excluding such one off net gain on disposal, the Group expects to record a loss of approximately HKD 427 million for the year ended 31 March 2018, representing a 30.1% improvement as compared to the adjusted net loss HKD 611 million excluding impairment loss on goodwill and reversal of impairment loss on investment in Fortress Group Limited for the year ended 31 March 2017.